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1 |  INTRODUCTION
Breast cancer (BC) comprised 23% of global cancer inci-
dence and 14% of global cancer mortality among women in 
2008 showing an increase in both incidence and mortality 
worldwide by the year 2012.1 Most BCs are diagnosed at an 
early stage for which the gold standard of treatment is breast- 
conserving surgery combined with radiation therapy (RT).2
The side effects of RT are typically transient skin reactions, 
but in rare cases, RT is also associated with the development 
of sarcoma (radiation- associated sarcoma [RAS]). The 15- 
year cumulative incidence of RAS was 0.28% among patients 
with BC treated during 1954- 1983.3 A significant relationship 
between radiation dose and the risk of subsequent sarcoma 
has been reported, with a relative risk of 30.6 for doses higher 
than 44 Gy compared to 14 Gy or lower.3 Cahan et al4 defined 
RAS arising in bone as sarcoma diagnosed in the RT field 
after a relatively long asymptomatic period before diagnosis 
of RAS with histologic proof of sarcoma. These criteria were 
later modified to include tissues adjacent to the path of the 
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Abstract
Radiation- associated sarcoma (RAS) is a rare complication of radiation therapy (RT) 
to breast cancer (BC). This study explored RAS after RT to BC in a nationwide 
population- based material. The Finnish Cancer Registry was queried for patients 
with BC treated during 1953- 2014 who were later diagnosed with a secondary 
sarcoma in 1953- 2014. Registry data, patient files, and sarcoma specimens were 
 analyzed to confirm diagnosis and location of RAS at or close to the RT target vol-
ume. A total of 132 512 patients were diagnosed with invasive BC during the study 
period. A subsequent sarcoma was diagnosed in 355 patients. After exclusion, 96 
RAS were identified. Angiosarcoma (AS) was the most prevalent histology in 50 
(52%) of 96 patients. However, the first radiation- associated AS was diagnosed in a 
patient treated for BC with breast- conserving surgery in 1984, and thereafter, the 
proportion of AS continuously increased. The 5- year sarcoma- specific survival was 
75.1% for RAS treated with a curative intent. The distribution of histologic subtypes 
of RAS has changed during the 60 years of this registry study. The first radiation- 
associated AS was diagnosed in 1989, and presently, AS is the most common histo-
logic subtype of RAS. It is possible that changes in BC treatment strategies are 
influencing the characteristics of RAS.
K E Y W O R D S
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radiation beam at risk of the development of RAS and a la-
tency period of at least 3- 4 years.5 The nomenclature in the 
literature is not always conclusive. The term RAS is some-
times used also in cases where RAS location has not been 
analyzed in relation to RT target volume.6 For this study, we 
define RAS as a sarcoma arising at or close to the RT target 
volume, and postirradiation sarcoma (PIS) as sarcoma arising 
in any location in an individual with the previous history of 
RT. Therefore, the incidence of PIS is higher than that of RAS.
The distribution of histologic subtypes among RAS 
differs from sporadic sarcomas. Angiosarcoma (AS) has 
been the most common subtype in recent studies,7-11 while 
osteosarcoma and undifferentiated pleomorphic sarcoma 
(UPS) have been the most common types in older series.12
The main aim in this study was to assess time trends in 
clinical characteristics and histologic subtypes of RAS after 
RT to invasive BC in a nationwide Finnish population be-
tween 1953 and 2014 exploiting registry data, detailed data 
from patient files, and histologic review.
2 |  PATIENTS AND METHODS
2.1 | Finnish Cancer Registry
The Finnish Cancer Registry (FCR) was established in 
1952, and it covers the whole population of Finland with ap-
proximately 5.6 million inhabitants presently. In 1961, the 
National Board of Health issued a by- law making reporting 
of cancers to FCR compulsory. All physicians, hospitals, 
and other institutions are obliged to send a notification of 
all diagnosed cancer cases. Pathology, cytology, and hema-
tology laboratories send a separate laboratory notification, 
mostly electronically nowadays. In addition, FCR contacts 
Statistics Finland annually to receive all death certificates 
where cancer is mentioned. FCR database includes close to 
complete national cancer data for solid malignant tumors di-
agnosed since 1953, which can be used for statistical and 
research purposes.13 In 2008, FCR changed to the ICD- O- 3 
(International Classification of Diseases for Oncology) cod-
ing system14 and converted earlier codes (based on ICD7) to 
match the ICD- O- 3. In Finland, all inhabitants have a unique 
personal ID code enabling reliable patient identification and 
follow- up. The FCR contains data on patient identity, pri-
mary tumor site and date of diagnosis, diagnostic methods, 
tumor morphology, and, if notified, also stage of the disease 
and primary treatment. Possible date and cause of death or 
emigration are checked and included on annual basis.
2.2 | Patient selection
Public healthcare system is mainly responsible for cancer 
diagnostics and treatment in Finland. Mammography- based 
screening for BC started in 1987 with high compliance.15 
After approval from the Joint Ethics Committee of Helsinki 
University Hospital and from the Ministry of Health and 
Social Affairs, we searched the files of the FCR for patients 
diagnosed with an invasive breast carcinoma (ICD- O- 314 
morphology codes 801.0, 801.3, 802.0, 802.1- 802.2, 803.2, 
804.1, 807.0, 807.4, 808.2, 812.3, 814.0- 814.1, 820.0, 820.1, 
821.1, 824.0, 824.6, 824.9, 825.5, 831.0, 832.3, 840.1, 844.0, 
848.0, 850.0- 850.4, 851.0, 852.0, 852.2, 852.3, 852.4, 853.0, 
854.0- 854.1, 854.3, 855.0, 856.0, 857.2, 857.5 with behav-
ior 3 and topography codes C50.0- C50.9) between 1953 and 
2014 (n = 132 512; Figure 1). The FCR database was then 
queried for secondary sarcomas occurring in these patients 
(ICD- O- 3 morphology codes 880.0- 893.6, 896.3- 896.4, 
898.0- 898.1, 899.0- 899.1, 902.0, 904.0- 904.4, 912.0- 914.0, 
917.0- 924.3, 926.0- 934.2, 953.5 with behavior 3; malignant, 
primary site) during 1953- 2014 (n = 355). No minimum la-
tency period was set. Registry data, patient records and pa-
thology reports were used to assess eligibility for the study. 
Treatment of BC and precise location of the sarcoma were 
analyzed from patient records to ensure that RT was used in 
BC treatment and that RAS was at or close to the RT target 
volume. In cases where sarcoma was not directly in RT tar-
get volume, treatment plans were reviewed to confirm that 
the sarcoma was at least partially located inside the irradi-
ated volume. The study period overlaps with a study from our 
institution including seven RAS patients after BC between 
1953 and 1988.12 Of these seven patients, we excluded one 
patient because RT was administered to BC local recurrence 
instead of primary BC (Figure 1).
2.3 | BC features
Detailed patient, tumor, and treatment characteristic data of 
BC were obtained from patient records and pathology reports. 
Histology (ductal, lobular, or other), grade (1- 3), estrogen- 
and progesterone receptor status (positive >10% by immu-
nohistochemistry), HER- 2 receptor overexpression (positive 
by in situ hybridization), and nodal involvement (present or 
absent) were recorded. Surgery (resection or mastectomy), 
chemotherapy (yes or no), endocrine therapy (yes or no), ax-
illary RT (yes or no), tumor bed RT boost (yes or no), and RT 
maximum dose and dose per fraction were recorded.
2.4 | Histologic reevaluation of RAS
All RAS samples were subjected to a histologic reevaluation 
by an experienced sarcoma pathologist (T.B.). We were un-
able to obtain the histologic specimens in eight RAS cases. 
Of these, five were AS cases diagnosed during 1989- 2014 
and three were RAS of other histologic subtypes diagnosed 
during 1994- 2012. These patients were nevertheless in-
cluded in the study based on the original pathology report, 
   | 4827SALMINEN Et AL.
which on review was considered diagnostic by our reviewer 
(T.B.). Lesions were graded according to the French grading 
system.16 One patient was excluded because diagnosis was 
changed from sarcoma to premalignant vascular lesion in the 
reevaluation.
2.5 | Follow- up
We defined the latency period as the interval from the first day 
of RT to BC to the histologic diagnosis of the RAS. Survival 
data were calculated from the histologic diagnosis of RAS to 
the last follow- up. We recorded both local recurrences and 
systemic recurrences from RAS and BC together with data 
on possible death and death cause.
2.6 | Statistical analyses
The number of expected cases was calculated based on na-
tional incidence rates and person- years at risk, stratified by 
age groups (5- year intervals), year of sarcoma diagnosis (5- 
year interval), and sex. The standardized incidence ratio (SIR) 
for secondary sarcoma after diagnosis of breast cancer was 
calculated as the ratio of the observed number of cases to the 
expected number of cases. Sarcoma- specific survival (SSS) 
F I G U R E  1  Flowchart of the study 
population; BC, breast cancer; DCIS, ductal 
carcinoma in situ; RAS, radiation- associated 
sarcoma; RT, radiotherapy
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was defined as the time from histologic diagnosis of RAS to 
death from RAS or treatment complication with censoring at 
the last follow- up date. SSS rates were calculated with the 
Kaplan- Meier method. IBM® SPSS® Statistics for Windows, 
Version 24.0. (Armonk, NY: IBM Corp.) and the R Project 
for Statistical Computing were used for all analyses.
3 |  RESULTS
A total of 132 512 patients were diagnosed with an in-
vasive BC during 1953 and 2014 (Figure 1), and this 
yielded a total of 1 257 946 patient- years at risk. Of these 
patients, 355 patients were diagnosed with a subsequent 
sarcoma during the study period vs 187.72 expected (SIR 
1.89 [95% confidence intervals 1.7- 2.09]). Seventy- four 
ASs were diagnosed vs 6.84 expected (SIR 10.81 [95% 
CI 8.53- 13.47]), and 281 other secondary sarcomas were 
diagnosed vs 180.88 expected (SIR 1.55 [95% CI 1.38- 
1.74]). A table describing the observed and expected 
numbers of sarcomas during the study period is listed in 
Appendix 1. Only four secondary AS were diagnosed in 
patients treated for BC during 1950- 1979 (SIR ranging 
from 0 to 13.2). In contrast, 69 secondary AS were found 
in patients treated for BC during 1980- 2009 (SIR ranging 
from 4.92 to 19.81).
After exclusion of cases not fulfilling the criteria for 
RAS, 96 RAS patients remained and comprised the study 
population (Figure 1). The mean age (SD) at BC and RAS 
diagnosis was 56 (11) and 68 (10) years, respectively. Fifty- 
two (54%) patients with BC were operated with breast- 
conserving surgery (Table 1). The year 1985 was a turning 
point in the surgical technique as only 10% of patients were 
operated with breast- conserving surgery before 1985 and 
66% after 1985. The total RT dose to BC varied from 28 
to 60 Gy and fraction size from 1.8 to 5 Gy. Most patients 
received a total dose of 50 Gy (n = 52) in 2- Gy fractions 
(n = 54). AS was the most common histologic subtype 
among RAS patients, accounting for 52% (50 of 96 patients) 
of RAS (Table 1). However, no AS was diagnosed during 
the first three decades of study (Figure 2). Instead, the first 
AS in our series was diagnosed in a patient receiving RT to 
BC in 1984, and the proportion of AS increased thereafter 
(Figure 2). All but one RAS were of intermediate or high 
grade (Table 2). Resected breast was the most common lo-
cation of RAS (46 of 96 cases). AS was the most common 
histologic subtype (37 of 46 patients) in the resected breast.
3.1 | Latency
The median latency of RAS varied depending on the time of 
BC diagnosis (Figure 2). The median latency was 11.0 years 
(range 0.6- 29.9) for all RAS, 7.7 years (range 0.6- 24.5) for 
AS, and 13.8 years (range 2.3- 29.9) for other sarcomas, 
respectively. For BC patients treated before 1984, the me-
dian latency of RAS was 16.4 years (range 11.0- 29.9). For 
BC patients treated in or after 1984, the median latency was 
8.2 years (range 0.6- 27.9) for all RAS, 7.7 years (range 0.6- 
24.5) for AS, and 10.6 years (range 2.3- 27.9) for other RAS, 
respectively.
3.2 | Treatment and survival
Eighty- two (85%) RAS patients were operated with curative 
intent. Nine RAS patients received adjuvant RT, and nine pa-
tients received adjuvant CT for RAS. Six BC patients devel-
oped systemic BC during follow- up. Five of these six patients 
were operated for RAS with curative intent. Median follow- up 
for survivors from the diagnosis of RAS was 4.4 years (range 
0.1- 32.6 years). At last follow- up, 46 (48%) of 96 RAS patients 
were alive with no evidence of BC or RAS. Forty patients died 
of RAS, four patients died of BC with no evidence of RAS, and 
four patients died of non- cancer- related causes. Two patients 
were alive with active BC with no evidence of RAS. Five- year 
SSS was 64.8% for all patients and 75.1% for patients treated 
with curative intent. For patients treated with curative intent, 
the 5- year SSS was 75.9% for AS and 76.1% for other RAS.
At RAS diagnosis, nine patients presented with metastatic 
disease. All these patients died of RAS with a median SSS 
of 0.43 years (range 0.1- 2.8). Twenty- two patients receiving 
primary treatment for local RAS with curative intent later de-
veloped systemic disease. Twenty patients died of systemic 
RAS, whereas two patients are alive with no evidence of RAS 
at 3.1 and 5.1 years after developing the systemic disease. 
The median SSS calculated from the diagnosis of metastatic 
F I G U R E  2  Trends in RAS incidence and median latency; 
AS, angiosarcoma; BC, breast cancer; RAS, radiation- associated 
angiosarcoma
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T A B L E  1  Breast cancer and treatment characteristics of the 96 breast cancer patients by radiation- associated sarcoma
Characteristic Total no. of patients, n (%) Angiosarcoma, n (%)




Mastectomy 44 (46) 11 (22) 33 (72) <0.05
Resection 52 (54) 39 (78) 13 (28)
Primary BC tumor size
<20 mm 53 (55) 34 (68) 19 (41) 0.127
≥20 mm 26 (27) 12 (24) 14 (30)
Missing 17 (18) 4 (8) 13 (28)
Histology
Ductal 61 (64) 35 (70) 26 (57) <0.05
Lobular 14 (15) 10 (20) 4 (9)
Other 15 (16) 4 (8) 11 (24)
Missing 6 (6) 1 (2) 5 (11)
Grade
1 19 (20) 16 (32) 3 (7) <0.05
2 41 (43) 26 (52) 15 (33)
3 9 (9) 2 (4) 7 (15)
Missing 27 (28) 6 (12) 21 (46)
Node status
Negative 53 (55) 34 (68) 19 (41) <0.05
Positive 42 (44) 16 (32) 26 (57)
Missing 1 (1) 0 1 (2)
Estrogen receptor status
Negative 8 (8) 3 (6) 5 (11) 0.439
Positive 57 (59) 38 (76) 19 (41)
Missing 31 (32) 9 (18) 22 (48)
Progesterone receptor status
Negative 17 (18) 12 (24) 5 (11) 0.316
Positive 46 (48) 29 (58) 17 (37)
Missing 33 (34) 9 (18) 24 (52)
HER2 overexpression
Negative 31 (32) 20 (40) 11 (24) 1.00
Positive 2 (2) 1 (2) 1 (2)
Missing 63 (66) 29 (58) 34 (74)
Adjuvant endocrine therapy
No 63 (66) 32 (64) 31 (67) 0.840
Yes 33 (34) 18 (36) 15 (33)
Adjuvant chemotherapy
No 76 (79) 48 (96) 28 (61) <0.05
Yes 20 (21) 2 (4) 18 (39)
Axillary lymph node RT
(Continues)
4830 |   SALMINEN Et AL.
disease was 0.6 years (range 0.02- 5.1) for AS and 0.7 years 
(range 0- 5.1) for other RAS.
4 |  DISCUSSION
The most important finding in this nationwide survey of RAS 
among 132 512 BC patients treated during 1953- 2014 was 
the increasing incidence of AS during the last three decades 
after treatment of BC. During the last three decades of study 
period, the incidence ratio of AS increased compared to the 
incidence ratio of other secondary sarcomas. This observa-
tion seemed to be due to the striking increment of AS among 
RAS of the breast. The first radiation- associated AS was di-
agnosed in a patient treated for BC in 1984. Thereafter, the 
incidence of AS steadily increased and in fact AS was the 
most common (52%) RAS histologic subtype in the current 
series. In our previous nationwide study on patients with 
RAS diagnosed during 1953- 1987 after RT for any malig-
nancy including BC, no case of AS was found.12
It is crucial to distinguish between true postirradiation 
sarcomas, that is sarcomas arising at or close to the RT tar-
get volume and other secondary sarcomas, as not all previous 
studies have analyzed the location of the sarcoma in relation 
to the RT target volume. This is of special importance in BC, 
as AS related to edema of the ipsilateral arm after surgery 
and radiation of the axilla has long been recognized as a clin-
ical entity, that is, the Stewart- Treves syndrome.17 The larg-
est study of sarcomas arising after treatment of BC hitherto, 
the SEER study, unfortunately does not distinguish between 
sarcomas arising in the RT target volume or elsewhere in 
the ipsilateral thoracic region or ipsilateral arm.6 Only a few 
cases of true RAS AS after RT for BC have been reported 
in the medical literature in the 70s and early 80s,18 whereas 
most postirradiation ASs developing before 1980s arose in 
lymphedematous arms.19-22 The only two AS among 11 sar-
comas judged to be induced by irradiation in 7620 patients 
treated for BC at Institut Gustave Roussy in France during 
1954- 1983 were located outside the RT target volume in the 
upper extremity.19 Ferguson et al20 reported four non- AS 
sarcomas at the treated chest wall and two AS in the swol-
len ipsilateral arm after mastectomy and irradiation among 
211 patients treated during 1927- 1970, and Davidson et al21 
reported two lymphangiosarcomas situated in irradiated ax-
illa after treatment for BC among the 20 patients diagnosed 
with RAS at the Royal Marsden Hospital 1954- 1985 after 
RT to any indication. In a Swedish population- based study 
on patients treated for BC during 1958- 1992, only two of 32 
AS described as being located “close to breast” were in fact 
located in the conserved breast whereas 30 were located in 
the edematous ipsilateral arm.22 Thus in these older series of 
patients with BC treated between 1927 and 1992, only four 
of 38 postirradiation AS may be classified as RAS according 
to the definition of Cahan, the majority of AS being due to 
lymphedema of the ipsilateral arm.
In contrast to older series, as in the present series an in-
creasing number of AS in RT target volume have been re-
ported in patients treated during and after the 1980s. Many 
patient series with confirmed location of RAS in the RT tar-
get volume, however, include only patients with AS and do 
not report RAS of all histologic subtypes. A few mixed series 
have, however, been published, and these are summarized in 
Table 3.7-12,23-34 The proportion of patients treated for BC 
varies in these series from 8% to 100%. Most AS (66/73) 
develop in patients treated for BC.8-11,23,24,26,27,29,32 Among 
patient series with RAS after primary tumor of any location 
extending in the 2000s, 21% (222/1040) of all cases were AS7-
11,27-34 compared to 5% (9/176) in series of RAS diagnosed 
within the 20th century.12,23-25 Unfortunately, the year of RT 
is given in only a few series. The five series, where the time 
of RT was stated, reveal a similar trend as the present study; 
the proportion of AS in two series with patients irradiated 
from 1953 to 1988 was 2%,12,24 while one series of patients 
irradiated from 1981 to 1997 reported an AS proportion of 
48%.9 The two series of patients irradiated from 1961 to 1996 
reported an intermediate frequency of AS of 23%.25,27
In a review from the Southern Swedish healthcare re-
gion on patients treated with RT for BC, the conclusion 
Characteristic Total no. of patients, n (%) Angiosarcoma, n (%)
Other sarcoma, n 
(%) P*
No 49 (51) 37 (74) 12 (26) <0.05
Yes 46 (48) 13 (26) 33 (72)
Missing 1 (1) 0 1 (2)
Radiation boost at tumor bed
No 79 (82) 37 (74) 42 (91) <0.05
Yes 17 (18) 13 (26) 4 (9)
HER2, human epidermal receptor 2; RT, radiation therapy.
*Either chi- squared or Fisher’s exact test.
T A B L E  1  (Continued)
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Characteristic








Breast 46 (48) 37 9
Upper trunk 16 (17) 7 9
Ablation scar 11 (11) 6 5
Shoulder 6 (6) 0 6
Sternum 5 (5) 0 5
Axilla 4 (4) 0 4
Lung 4 (4) 0 4
Scapula 3 (3) 0 3
Upper arm 1 (1) 0 1
Site
Soft tissue 88 (92) 50 38
Bone 8 (8) 0 8
Metastases at presentation
Yes 9 (9) 0 9

















1 1 (1) 0 1 (2)
2 22 (23) 8 (16) 14 (30)
3 70 (73) 39 (78) 31 (67)
Missing 3 (3) 3 (6) 0
Operated with curative intent
Yes 82 (85) 47 (94) 35 (76)
No 14 (15) 3 (6) 11 (24)
Adjuvant RTa
Yes 9 (11) 1 (2) 8 (23)
No 73 (89) 46 (98) 27 (77)
Adjuvant CTa
Yes 9 (11) 5 (10) 4 (11)
No 73 (89) 42 (89) 31 (89)
CT, chemotherapy; RAS, radiation- associated sarcoma; RT, radiation therapy; UPS, undifferentiated pleomor-
phic sarcoma.
aOf the 82 patients treated with curative intention.
T A B L E  2  Radiation- associated 
sarcoma and treatment characteristics of the 
96 patients by radiation- associated sarcoma
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was that “the clinical presentation of AS has changed, par-
allel with altered treatment principles for BC”.35 This was 
based on a finding that of the 31 patients developing AS, 14 
females treated during 1949- 1988 developed AS in edema-
tous arms (Stewart- Treves syndrome) after median latency 
of 11 years, whereas 17 patients treated during 1980- 2005 
developed AS in the irradiated field on the thoracic wall 
after median of 7.3 years.35 A similar result was apparent 
in a study from the Institut Gustave Roussy, France, by 
Rubino et al3 where 7711 patients treated for BC during 
1954- 1983 were analyzed for secondary sarcomas. Three 
patients treated with mastectomy and external RT during 
1970- 1976 developed AS in the upper arm, whereas one 
patient with BC treated with tumorectomy and RT in 1983 
developed an in- field AS.3 Our results are confirmatory 
with the first in- field AS occurring in a patient receiving 
RT to BC during the 1980s, and a steady increase in inci-
dence thereafter.
One key strength of the current study was the truly nation-
wide material based on the reliable Finnish Cancer Registry 
with nearly 100% completeness in solid tumors13 Furthermore, 
all patient records were assessed for detailed information. 
Although our study has many strengths, some weaknesses 
need to be discussed. Firstly, a small proportion (8%) of 
RAS samples were not available for reevaluation. Histologic 
reevaluation of RAS samples yielded exclusion of only one 
patient with atypical vascular lesion possibly a precursor of 
AS. Therefore, the impact of missing histologic reevaluation 
on our results is probably small. Sarcoma, especially AS, has a 
specific morphology compared to recurrent carcinoma. Thus, 
we felt comfortable including also unavailable specimen after 
assessment of the initial pathology reports by an experienced 
sarcoma pathologist. Another limitation concerning especially 
the study of time trends is inherent to the characteristics of 
RAS itself. Mery et al6 reported the risk of developing soft tis-
sue sarcoma after RT to BC peaking at 10 years and remaining 
T A B L E  3  Patient series reporting all histologic subtypes of in- target radiation- associated sarcomas




AS in BC 
patients
n % n %
Wiklund 
et al12
1953- 1988 B/S 21 1953- 1988 1 0/33 0 0/7 0
Laskin et al23 NA S 23 1954- 1986 2 1/53 2 0/12 0
Kuten et al24 1953- 1978 S 100 1968- NA 1/7 14 1/7 14
Pierce et al25 1968- 1985 S 100 NA NA 0/3 0 0/3 0
Lagrange 
et al26
NA B/S 42 1975- 1995 3 7/80 9 6/34 18
Thijssens 
et al27
1961- 1996 B/S 52 1978- 2003 3 7/27a 26 7/14 50
Kalra et al7 NA B 19 1978- 2005 NA 0/42 0 0/8 0
Erel et al8 NA B/S 100 1978- 2009 NA 5/25 20 5/25 20
Bjerkehagen 
et al28
NA B/S 20 1980- 2008 2 12/106 11 NA NA
Gladdy et al29 NA S 34 1982- 2007 0.5 27/130 21 22/44 50
Kirova et al9 1981- 1997 B/S 100 NA 3 13/27 48 13/27 48
Mavrogenis 
et al10
NA B/S 8 1985- 2011 3 1/52 2 1/4 25
De Smet 
et al30
NA B/S 50 1987- 2007 1 17/46 37 NA NA
Riad et al31 NA S 34 1989- 2009 3 8/44 18 NA NA
Neuhaus 
et al32
NA S 51 1990- 2005 3 9/67 13 9/34 27
Penel et al33 NA S 45 1997- 2005 3 4/22 18 NA NA
Kim et al11 NA B/S 27 2000- 2014 0.5 2/33 6 2/9 22
Zhang et al34 NA B/S 51 2000- 2014 0.5 117/419 28 NA NA
AS, angiosarcoma; B, bone; BC breast cancer; NA, not available; RAS, radiation- associated sarcoma; RT, radiation therapy; S, soft tissue.
aFirst AS diagnosed in 1995.
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elevated up to 20 years after RT. The long latency time affects 
the distribution of latency times in the present series. Latency 
appears to be misleadingly short for cases at the beginning and 
end of the follow- up period due to left and right truncation 
of the distribution of latency times. This is partially reflected 
in the variation of RAS median latency shown in Figure 2. 
Statistical methods utilizing left or right censoring are not ap-
plicable in the present study, as the cancer registry does not 
include reliable data on exposure of RT among BC cases.
The reason for the increase in AS incidence is unclear, but 
one possible factor is RT administered after breast resection 
rather than mastectomy. This cannot, however, be the only 
explanation because AS developed after breast ablation in 11 
(11/50 AS) patients. Increased use of medical adjuvant therapy 
cannot be the reason either, as only 18 AS patients received 
adjuvant endocrine therapy and two AS patients received cy-
totoxic treatment. Estimation of the risk of RAS in irradiated 
BC patients as a function of time is beyond the scope of the 
current study due to the limitations described above. We can, 
however, speculate that as the number of patients exposed to 
RT as part of the treatment for BC increases6 and survival for 
BC improves,36 RAS should show an increase in incidence. 
The current study offers no evidence that the incidence of RAS 
of other histologic subtypes than AS is increasing.
Our material provides a unique view of RAS after BC in 
Finland. Patients were identified from a national, compre-
hensive cancer registry. Our study covers all RAS diagnosed 
between 1953 and 2014 after BC, providing an extensive 
time span. BC incidence has increased significantly in 
Finland (39/100 000 in 1967 and 161/100 000 in 2012), and 
the 5- year survival of BC patients improved (53% during 
1965- 1969 and 88% during 2010- 2014).36 These factors 
are likely to influence the incidence of RAS in combination 
with the evolution of RT techniques during past decades. We 
found that the total number of RAS increased during the last 
30 years, which at least partly may relate to a higher num-
ber of patients exposed. The most striking finding, however, 
was the emerging of and continuous increase of AS after BC 
treated in the 1980s or later, while no increase in the inci-
dence of other histologic types was seen. Further research is 
required to determine the cause of this change in the histo-
logic distribution of RAS.
ACKNOWLEDGMENT
This study was supported by the Competitive Research 
Funding of Helsinki University Hospital and the Finnish 
Cancer Society. They had no role in the study design, data 
interpretation, or article writing.
CONFLICT OF INTEREST
The authors made no disclosures.
ORCID
Mika M. Sampo  http://orcid.org/0000-0001-9454-4495 
REFERENCES
 1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN. Cancer 
Incidence and Mortality Worldwide. Lyon, France: International 
Agency for Research on Cancer; 2013. http://globocan.iarc.fr.
 2. Fisher B, Anderson S, Bryant J, et al. Twenty- year follow- up of a 
randomized trial comparing total mastectomy, lumpectomy, and 
lumpectomy plus irradiation for the treatment of invasive breast 
cancer. N Engl J Med. 2002;347:1233‐1241.
 3. Rubino C, Shamsaldin A, Le MG, et al. Radiation dose and risk of 
soft tissue and bone sarcoma after breast cancer treatment. Breast 
Cancer Res Treat. 2005;89:277‐288.
 4. Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley 
BL. Sarcoma arising in irradiated bone: report of eleven cases. 
1948. Cancer. 1998;82:8‐34.
 5. Arlen M, Higinbotham NL, Huvos AG, Marcove RC, Miller 
T, Shah IC. Radiation- induced sarcoma of bone. Cancer. 
1971;28:1087‐1099.
 6. Mery CM, George S, Bertagnolli MM, Raut CP. Secondary sarco-
mas after radiotherapy for breast cancer: sustained risk and poor 
survival. Cancer. 2009;115:4055‐4063.
 7. Kalra S, Grimer RJ, Spooner D, Carter SR, Tillman RM, Abudu 
A. Radiation- induced sarcomas of bone: factors that affect out-
come. J Bone Joint Surg Br. 2007;89:808‐813.
 8. Erel E, Vlachou E, Athanasiadou M, Hassan S, Chandrasekar CR, 
Peart F. Management of radiation- induced sarcomas in a tertiary 
referral centre: a review of 25 cases. Breast. 2010;19:424‐427.
 9. Kirova YM, Vilcoq JR, Asselain B, Sastre-Garau X, Fourquet 
A. Radiation- induced sarcomas after radiotherapy for breast 
carcinoma: a large- scale single- institution review. Cancer. 
2005;104:856‐863.
 10. Mavrogenis AF, Pala E, Guerra G, Ruggieri P. Post- radiation 
sarcomas. Clinical outcome of 52 Patients. J Surg Oncol. 
2012;105:570‐576.
 11. Kim KS, Chang JH, Choi N, et al. Radiation- induced sarcoma: 
a 15- year experience in a single large tertiary referral center. 
Cancer Res Treat. 2016;48:650‐657.
 12. Wiklund TA, Blomqvist CP, Raty J, Elomaa I, Rissanen P, 
Miettinen M. Postirradiation sarcoma, Analysis of a nationwide 
cancer registry material. Cancer. 1991;68:524‐531.
 13. Leinonen MK, Miettinen J, Heikkinen S, Pitkaniemi J, Malila 
N. Quality measures of the population- based Finnish Cancer 
Registry indicate sound data quality for solid malignant tumours. 
Eur J Cancer. 2017;77:31‐39.
 14. Fritz AG, Percy C, Jack A, Sobin LH, Parkin MD. International 
Classification of Diseases for Oncology (ICD-O), 3rd edn. 
Geneva, Switzerland: World Health Organization; 2000.
 15. Hakama M, Pukkala E, Heikkila M, Kallio M. Effectiveness of 
the public health policy for breast cancer screening in Finland: 
population based cohort study. BMJ. 1997;314:864‐867.
 16. Coindre JM. Grading of soft tissue sarcomas: review and update. 
Arch Pathol Lab Med. 2006;130:1448‐1453.
 17. Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy 
lymphedema; a report of six cases in elephantiasis chirurgica. 
Cancer. 1948;1:64‐81.
4834 |   SALMINEN Et AL.
 18. Edeiken S, Russo DP, Knecht J, Parry LA, Thompson RM. 
Angiosarcoma after tylectomy and radiation therapy for carci-
noma of the breast. Cancer. 1992;70:644‐647.
 19. Taghian A, de Vathaire F, Terrier P, et al. Long- term risk of sar-
coma following radiation treatment for breast cancer. Int J Radiat 
Oncol Biol Phys. 1991;21:361‐367.
 20. Ferguson DJ, Sutton HG Jr, Dawson PJ. Late effects of adjuvant 
radiotherapy for breast cancer. Cancer. 1984;54:2319‐2323.
 21. Davidson T, Westbury G, Harmer CL. Radiation- induced soft- 
tissue sarcoma. Br J Surg. 1986;73:308‐309.
 22. Karlsson P, Holmberg E, Samuelsson A, Johansson KA, Wallgren 
A. Soft tissue sarcoma after treatment for breast cancer- a Swedish 
population- based study. Eur J Cancer. 1998;34:2068‐2075.
 23. Laskin WB, Silverman TA, Enzinger FM. Postradiation soft tissue 
sarcomas. An analysis of 53 cases. Cancer. 1988;62:2330‐2340.
 24. Kuten A, Sapir D, Cohen Y, Haim N, Borovik R, Robinson E. 
Postirradiation soft tissue sarcoma occurring in breast cancer pa-
tients: report of seven cases and results of combination chemother-
apy. J Surg Oncol. 1985;28:168‐171.
 25. Pierce SM, Recht A, Lingos TI, et al. Long- term radiation com-
plications following conservative surgery (CS) and radiation ther-
apy (RT) in patients with early stage breast cancer. Int J Radiat 
Oncol Biol Phys. 1992;23:915‐923.
 26. Lagrange JL, Ramaioli A, Chateau MC, et al. Sarcoma after ra-
diation therapy: retrospective multiinstitutional study of 80 his-
tologically confirmed cases. Radiation Therapist and Pathologist 
Groups of the Federation Nationale des Centres de Lutte Contre 
le Cancer. Radiology. 2000;216:197‐205.
 27. Thijssens KM, van Ginkel RJ, Suurmeijer AJ, et  al. Radiation- 
induced sarcoma: a challenge for the surgeon. Ann Surg Oncol. 
2005;12:237‐245.
 28. Bjerkehagen B, Smastuen MC, Hall KS, Skjeldal S, Smeland S, 
Fossa SD. Why do patients with radiation- induced sarcomas have 
a poor sarcoma- related survival? Br J Cancer. 2012;106:297‐306.
 29. Gladdy RA, Qin LX, Moraco N, et  al. Do radiation- associated 
soft tissue sarcomas have the same prognosis as sporadic soft tis-
sue sarcomas? J Clin Oncol. 2010;28:2064‐2069.
 30. De Smet S, Vandermeeren L, Christiaens MR, et al. Radiation- 
induced sarcoma: analysis of 46 cases. Acta Chir Belg. 
2008;108:574‐579.
 31. Riad S, Biau D, Holt GE, et al. The clinical and functional out-
come for patients with radiation- induced soft tissue sarcoma. 
Cancer. 2012;118:2682‐2692.
 32. Neuhaus SJ, Pinnock N, Giblin V, et al. Treatment and outcome of 
radiation- induced soft- tissue sarcomas at a specialist institution. 
Eur J Surg Oncol. 2009;35:654‐659.
 33. Penel N, Grosjean J, Robin YM, Vanseymortier L, Clisant S, 
Adenis A. Frequency of certain established risk factors in soft 
tissue sarcomas in adults: a prospective descriptive study of 658 
cases. Sarcoma. 2008;2008:459386.
 34. Zhang AY, Judson I, Benson C, et  al. Chemotherapy with 
radiotherapy influences time- to- development of radiation- 
induced sarcomas: a multicenter study. Br J Cancer. 
2017;117:326‐331.
 35. Styring E, Fernebro J, Jonsson PE, et al. Changing clinical pre-
sentation of angiosarcomas after breast cancer: from late tumors 
in edematous arms to earlier tumors on the thoracic wall. Breast 
Cancer Res Treat. 2010;122:883‐887.
 36. Engholm G, Ferlay J, Christensen N, et  al. NORDCAN: can-
cer incidence, mortality, prevalence and survival in the Nordic 
Countries. Association of the Nordic Cancer Registries. Danish 
Cancer Society; 2015. Version 7.2 (16.12.2015). http://www.ancr.
nu.
How to cite this article: Salminen SH, Sampo MM, 
Böhling TO, Tuomikoski L, Tarkkanen M, Blomqvist 
CP. Radiation- associated sarcoma after breast cancer in 
a nationwide population: Increasing risk of 
angiosarcoma. Cancer Med. 2018;7:4825–4835. https://
doi.org/10.1002/cam4.1698
   | 4835SALMINEN Et AL.
APPENDIX 1





years SIR (95% CI) Observed Expected
Person- 
years SIR (95% CI)
1950- 1954 0 0.02 11688.5 0 (0- Inf) 1 1.30 11688.5 0.77 (0.11- 5.44)
1955- 1959 1 0.08 31951.8 13.12 (1.85- 93.14) 1 3.54 31951.8 0.28 (0.04- 2)
1960- 1964 0 0.12 40024.2 0 (0- Inf) 8 4.72 40024.2 1.69 (0.85- 3.39)
1965- 1969 1 0.19 51755.4 5.15 (0.73- 36.57) 11 6.50 51755.4 1.69 (0.94- 3.06)
1970- 1974 0 0.27 69831.6 0 (0- Inf) 18 9.17 69831.6 1.96 (1.24- 3.11)
1975- 1979 2 0.34 87673.0 5.81 (1.45- 23.24) 28 11.99 87673.0 2.34 (1.61- 3.38)
1980- 1984 4 0.51 110413.6 7.82 (2.94- 20.85) 22 15.85 110413.6 1.39 (0.91- 2.11)
1985- 1989 4 0.81 146975.6 4.92 (1.85- 13.11) 39 21.88 146975.6 1.78 (1.3- 2.44)
1990- 1994 11 0.99 168322.8 11.12 (6.16- 20.07) 30 25.09 168322.8 1.2 (0.84- 1.71)
1995- 1999 22 1.11 184461.7 19.81 
(13.04- 30.08)
42 27.41 184461.7 1.53 (1.13- 2.07)
2000- 2004 16 1.11 173883.8 14.4 (8.82- 23.51) 42 25.99 173883.8 1.62 (1.19- 2.19)
2005- 2009 12 0.90 128567.1 13.3 (7.55- 23.42) 29 19.21 128567.1 1.51 (1.05- 2.17)
2010- 2015 1 0.39 52396.9 2.59 (0.36- 18.37) 10 8.22 52396.9 1.22 (0.65- 2.26)
BC, breast cancer; CI, confidence interval; Inf, infinity; SIR, standardized incidence ratio.
